Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain with intent to treat or currently treated with opioids. Exclusion criteria will include current cannabis use, severe medical illness or lacking in capacity to be involved in study. TC and TP will be prescribed for use TID in predefined dosages and quantities.
Epistemonikos ID: 4ba9342bf37572794cdd5dd373ed88eff3fc391d
First added on: May 09, 2024